IIT

iCell Presents Positive New Follow-up Clinical Data Confirming BCMA CD19 cCAR Safely Delivers Long-term Medication Free Complete Remission from Systemic Lupus Erythematosus & Lupus Nephritis at EULAR 2024

Retrieved on: 
星期三, 六月 12, 2024
Biotechnology, Health, Genetics, Clinical Trials, Oncology, UTI, Congress, European Alliance, SLE, IIT, Proteinuria, CD19, Patient, Research, Urinary tract infection, Lupus nephritis, MFR, B cell, CRS, Class, Cancer, CKD, Lupus, COVID-19, Infection, Chronic kidney disease, Immunoglobulin G, BCMA, Hospital, Immunoglobulin A, Autoantibody, Immunoglobulin M, EULAR, CCAR, Pharmaceutical industry

All six patients diagnosed with LN less than 10 years ago had a complete renal response with a mean normal 24-hour protein (>90% decline from screening).

Key Points: 
  • All six patients diagnosed with LN less than 10 years ago had a complete renal response with a mean normal 24-hour protein (>90% decline from screening).
  • Renal function improved in 2/4 LN patients diagnosed more than 10 years ago or with chronic kidney disease (CKD).
  • Patients achieved symptom-free and medication-free remission (MFR), with post-cCAR follow-up to 46-months with 11/12 (92%) meeting the DORIS criteria for complete remission.
  • The data suggest that cCAR therapy was safe and effective in inducing MFR and depleting disease-causing autoantibodies in SLE and LN patients.

HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting

Retrieved on: 
星期四, 五月 23, 2024
HLA, Patient, Progression-free survival, Abstract (summary), Survival, Arenavirus, Pembrolizumab, IIT, Neck, OPC, University, CDT, Overalls, Neoplasm, Head, Safety, Disease, CPS, Cancer, ASCO, Mutation, Chemoradiotherapy, Peptide, CD8, PD-L1, DCR, Annual general meeting, Oropharyngeal cancer, Pharmaceutical industry

The abstract reported data as of January 12, 2024, and included 42 patients treated with HB-200 plus pembrolizumab.

Key Points: 
  • The abstract reported data as of January 12, 2024, and included 42 patients treated with HB-200 plus pembrolizumab.
  • This subpopulation is representative of patients eligible for the Company’s pivotal Phase 2/3 trial, which will begin enrolling patients in the fourth quarter of 2024.
  • Additional data will be presented in the Head and Neck Oral Abstract Session at the ASCO 2024 Annual Meeting on June 4, at 11:09 a.m. CDT.
  • During the presentation, preliminary progression-free survival and overall survival data will be shared for the first time.

BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

Retrieved on: 
星期四, 五月 16, 2024
Esophageal cancer, University School, Docetaxel, IND, EGFR, Monroe Dunaway Anderson, Drug discovery, Research, PROTAC, Johns Hopkins Hospital, Respiratory disease, International Association, Publication, Internet, PD-1, CSO, MOA, CNS, Cayetano Heredia University, Research institute, Radiation, OS, Research and development, Immunotherapy, Eli Lilly, Lung cancer, Entrepreneurship, Howard Hughes Medical Institute, Radiation therapy, University, RBM39, Protein, NSCLC, MD Anderson Cancer Center, Cancer, Society, Microtubule, Lung, Patient, IIT, HNSCC, Oncology, Therapy, Biomarker, Abstract, Virology, TPD, Pharmaceutical industry

(Moffitt Cancer Center), and Steven Lin, M.D., Ph.D. (MD Anderson Cancer Center), as well as BeyondSpring and SEED Therapeutics management.

Key Points: 
  • (Moffitt Cancer Center), and Steven Lin, M.D., Ph.D. (MD Anderson Cancer Center), as well as BeyondSpring and SEED Therapeutics management.
  • Plinabulin alone or in combination has been well-tolerated in >700 cancer patients in two positive phase 3 studies.
  • Following the plinabulin presentations, Dr. Lan Huang discussed how BeyondSpring’s majority-owned subsidiary, SEED Therapeutics, uses its proprietary TPD platforms to develop “molecular glues” for undruggable targets.
  • Dr. Lin runs a translational research team that evaluates biomarkers for treatment response and disease outcomes after cancer therapy.

ComEd Completes One of Nation’s First Neighborhood Scale Community Microgrids in Bronzeville on Chicago’s South Side

Retrieved on: 
星期五, 五月 24, 2024
Utilities, Energy, Chicago Police Department, EV, De La Salle Institute, Restaurant, Mentorship, Mathematics, Commonwealth Edison, IIT, News, Argonne National Laboratory, DOE, LED, Commonwealth, Illinois Institute of Technology, EXC, Computer, Rain, Engineering, Weather, BCM, CHA, Exelon, 38th Street, 33rd Street, Student, Electricity, Electrical engineering, Software, State Street, Primary energy, Quality of life, City, Renewable energy

ComEd today joined leaders from the U.S. Department of Energy (DOE), the City of Chicago and the community of Bronzeville to mark the completion of the Bronzeville Community Microgrid (BCM) – one of the nation’s first neighborhood scale community microgrids.

Key Points: 
  • ComEd today joined leaders from the U.S. Department of Energy (DOE), the City of Chicago and the community of Bronzeville to mark the completion of the Bronzeville Community Microgrid (BCM) – one of the nation’s first neighborhood scale community microgrids.
  • “This project is the culmination of nearly a decade of work with the Department of Energy, ComEd, and Bronzeville investing to make this a reality,” U.S.
  • Bronzeville was selected following a comprehensive study to evaluate locations where a microgrid could be located.
  • For more information visit ComEd.com , and connect with the company on Facebook , Instagram , LinkedIn , X , and YouTube .

iCell Gene Therapeutics Announces Positive Clinical Data from Investigator Initiated Phase 1 Trial Evaluating BCMA-CD19 Compound CAR in Patients with Systemic Lupus Erythematosus/Lupus Nephritis Published in Annals of the Rheumatic Diseases

Retrieved on: 
星期四, 五月 23, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, European Alliance, Patient, Survival, Lupus, CCAR, Data, Infection, IIT, COVID-19, Class, Patent, T cell, SLE, Clinical trial, CD19, Immunoglobulin M, IND, Safety, Urinary tract infection, Autoantibody, MFR, Cancer, Autoimmunity, Cyclophosphamide, Hospital, EULAR, B cell, BCMA, Glucocorticoid, Canadian Aviation Regulations, LN, Lupus nephritis, CRS, Pharmaceutical industry

The clinical trial evaluated the safety and efficacy of a complete humoral reset of both long-lived plasma cells and B cells in 13 systemic lupus erythematosus (SLE) patients treated with iCell’s cCAR, including 11 patients with SLE and lupus nephritis (LN).

Key Points: 
  • The clinical trial evaluated the safety and efficacy of a complete humoral reset of both long-lived plasma cells and B cells in 13 systemic lupus erythematosus (SLE) patients treated with iCell’s cCAR, including 11 patients with SLE and lupus nephritis (LN).
  • These patients achieved symptom-free and medication-free remission (MFR), with post-cCAR follow-up to 46 months.
  • There are currently no approved therapies that deliver MFR in SLE/LN patients who are at high risk of long-term organ damage and kidney transplant.
  • The data suggest that cCAR therapy was safe and effective in inducing MFR and depleting disease-causing autoantibodies in SLE and LN patients.

Cancer Moonshot Gets a Booster Shot from This AI-Driven Clinical Research Platform

Retrieved on: 
星期一, 五月 13, 2024
Partnership, CTMS, Patient, Cell, Rest, Radius, IIT, Complex, Hope, CCRP, Tata Memorial Centre, Clinical trial, Developing country, Safety, Pulitzer Prize, Western world, Conference, Cancer Moonshot, Disease, Biography, Emperor, Connect, Data management, Moonshot, AI, Death, Cancer, Research, Gene, EDC, Brain, Leukemia, Associate, BIO, Clinical data management, Society, Electronic data capture, RWD, NIH, Pharmaceutical industry

MANASSAS, Va., May 13, 2024 /PRNewswire-PRWeb/ -- The clinical trial landscape is marred by persistent operational inefficiencies that have only been marginally addressed by the proliferation of technology and the shift to remote trial operations. 2024 is seeing a surge in the fight against cancer, with cancer clinical trials dominating the rest. (1) Dr. Rajasimha notes, "Despite the AI revolution, digital transformation initiatives, and the advent of remote operations, the core goals of clinical trials—to assess the safety and efficacy of treatment options—remain unchanged. They are also getting increasingly inefficient, expensive, longer, and complex due to short-sighted point solutions that address specific parts of the drug development process. We need comprehensive solutions to this nagging problem - a piecemeal approach has resulted in 90% failure rate of candidate drugs in the 'valley of death' and 30% trial terminations due to poor enrollment." (2)

Key Points: 
  • President Biden's loss of his beloved son to brain cancer in 2015 inspired the Cancer Moonshot initiative.
  • 2024 is seeing a surge in the fight against cancer, with cancer clinical trials dominating the rest.
  • His commitment aligns with the audacious goals of the Whitehouse's Cancer Moonshot initiative, forging a powerful partnership towards excellence in Cancer clinical research and treatment.
  • Harnessing cutting-edge technologies like AI, driving breakthroughs in precision cancer treatment options, as validated by recent NIH research.

WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval

Retrieved on: 
星期五, 五月 10, 2024
Ionization, Patient, Esophageal cancer, IIT, Toxicity, Patent, Nasopharyngeal carcinoma, NPC, Messenger, FDA, Cervical cancer, Malignancy, Breast cancer, Vaccine, Bone marrow, EB, Lipid, Multiple sclerosis, Research, Stomach, Lupus, Cancer, Lung cancer, Liver cancer

CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.

Key Points: 
  • CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.
  • This landmark achievement marks the world's first approval of an EB virus-related mRNA therapeutic cancer vaccine.
  • The FDA approval of WGc-043 represents a significant advance in cancer treatment, offering new hope to patients with advanced EB virus-related cancers.
  • EB virus is highly correlated with more than ten malignancies, including nasopharyngeal carcinoma (NPC), natural killer T-cell lymphoma (NKTL), gastric cancer, lung cancer, liver cancer, esophageal cancer, breast cancer, cervical cancer, and autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus.

WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval

Retrieved on: 
星期五, 五月 10, 2024
Ionization, Patient, Esophageal cancer, IIT, Toxicity, Patent, Nasopharyngeal carcinoma, NPC, Messenger, FDA, Cervical cancer, Malignancy, Breast cancer, Vaccine, Bone marrow, EB, Lipid, Multiple sclerosis, Research, Stomach, Lupus, Cancer, Lung cancer, Multimedia, Liver cancer

CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.

Key Points: 
  • CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.
  • This landmark achievement marks the world's first approval of an EB virus-related mRNA therapeutic cancer vaccine.
  • The FDA approval of WGc-043 represents a significant advance in cancer treatment, offering new hope to patients with advanced EB virus-related cancers.
  • EB virus is highly correlated with more than ten malignancies, including nasopharyngeal carcinoma (NPC), natural killer T-cell lymphoma (NKTL), gastric cancer, lung cancer, liver cancer, esophageal cancer, breast cancer, cervical cancer, and autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus.

ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Retrieved on: 
星期一, 五月 6, 2024
PSMA, FDA, Net, University, Part, DLBCL, EDT, City, CRS, Safety, PIN, University of Miami, Pancreatic cancer, Infrared spectroscopy correlation table, Research, Hematology, Insurance, PR, MD, Growth, ICU, Rituximab, Follicular lymphoma, ADC, Patient, Therapeutic index, Sarcoma, S&M, Diffuse large B-cell lymphoma, NHL, Cytokine release syndrome, Marketing, IIT, Advertising, Therapy, NSCLC, Spacecraft, AXL, Lung cancer, Pharmaceutical industry

Sequential quarter-over-quarter growth in the first quarter of 2024 continued, with sales volume increasing in both community and academic settings.

Key Points: 
  • Sequential quarter-over-quarter growth in the first quarter of 2024 continued, with sales volume increasing in both community and academic settings.
  • Net product revenues were $17.8 million for the first quarter 2024, compared to $19.0 million for the first quarter 2023.
  • R&D expenses were $25.7 million for the first quarter 2024, compared to $38.4 million for the first quarter 2023.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss first quarter 2024 financial results and provide a company update today at 8:30 a.m. Eastern Time.

Chief Information Security Officer Tellis Williams Represents Dream Exchange at Global Cyber Security Initiative 2024

Retrieved on: 
星期三, 五月 8, 2024
Law, Information technology, CISO, GCSI, Conference, Artificial intelligence, History, Microsoft, Trust, Financial services, IIT, Organization, Medical device

CHICAGO, May 8, 2024 /PRNewswire/ -- Dream Exchange, the first minority-controlled stock exchange in the history of the United States is proud to announce that its Chief Information Security Officer ("CISO"), Tellis Williams, was featured in a fireside chat at the esteemed Global Cyber Security Initiative (GCSI) Annual Conference held at the Illinois Institute of Technology ("IIT") on Thursday, April 18, 2024.

Key Points: 
  • CHICAGO, May 8, 2024 /PRNewswire/ -- Dream Exchange, the first minority-controlled stock exchange in the history of the United States is proud to announce that its Chief Information Security Officer ("CISO"), Tellis Williams, was featured in a fireside chat at the esteemed Global Cyber Security Initiative (GCSI) Annual Conference held at the Illinois Institute of Technology ("IIT") on Thursday, April 18, 2024.
  • "It was an honor to represent Dream Exchange at the GCSI Annual Conference and engage with such an impressive group of cybersecurity opinion leaders," said Tellis Williams.
  • "As the financial sector continues to evolve, Dream Exchange is poised to make history as the first minority-controlled stock exchange.
  • Joe Cecala, Founder and CEO of Dream Exchange , commended Williams' participation, stating, "Tellis Williams' expertise and leadership in cybersecurity have been invaluable to Dream Exchange.